Aarti pharma labs Limited has provided clarification to BSE regarding a delay in regulatory disclosure under SEBI regulations. The company submitted the explanation on February 13, 2026, addressing concerns about missing the mandatory 24-hour disclosure timeline.

Disclosure Delay Details

The pharmaceutical company's clarification pertains to a Corporate Announcement that was submitted on February 6, 2026, at 04:21:06 PM under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The regulation mandates that material events be disclosed to stock exchanges within 24 hours of occurrence.

Reason for Delay

According to the company's explanation, the delay occurred due to operational circumstances beyond immediate control. The email communication containing the relevant query was received by the concerned official who was on leave from February 3 to February 5, 2026. This absence resulted in the matter not being addressed within the stipulated regulatory timeline.

The company emphasized that the delay was inadvertent and occurred only because the responsible official was unavailable during the critical period when the disclosure requirement arose.

Company Response

Aarti Pharmalabs Limited has formally requested BSE to take the clarification on record, acknowledging the circumstances that led to the delayed disclosure. The clarification letter was signed by Jeevan Bhargav Mondkar, Company Secretary and Legal Head, who holds ICSI membership number A22565.

The company's proactive approach in providing detailed explanation demonstrates its commitment to regulatory compliance and transparency with stock exchange authorities, despite the inadvertent delay in meeting the disclosure timeline.

Aarti Pharmalabs Limited has issued a corrigendum to correct a typographical error in its dividend record date intimation, ensuring accurate regulatory compliance for its dividend declaration.

Corrigendum Details

On February 10, 2026, Aarti Pharmalabs Limited filed a corrigendum with both BSE and National Stock Exchange of India Limited to rectify an error in its dividend record date intimation dated February 09, 2026. The correction specifically addresses a typographical mistake in the mention of the financial year for which the dividend was declared.

Regulatory Filing Information

The corrigendum was submitted to both major stock exchanges where the company's shares are listed. The filing ensures compliance with Regulation 42 requirements for dividend-related communications.

Company Confirmation

Jeevan Mondkar, Company Secretary and Legal Head of Aarti Pharmalabs Limited, confirmed that except for the financial year correction, no other changes were made to the original intimation dated February 09, 2026. The company emphasized that all other details in the dividend record date intimation remain unchanged and valid.

The corrigendum demonstrates the company's commitment to maintaining accurate regulatory filings and ensuring shareholders receive correct information regarding dividend-related matters for Financial Year 2025-26.